Assignee
BEIGENE SWITZERLAND GMBH
CH·18 granted patents·66 pending applications·73 citations·filing 2017–2025
Top patents by PatentIndex Score
84 records- 0198US11186637B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2021·Granted Nov 30, 2021·11 cites·8 claims
- 0298US11142528B2Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulatorsBEIGENE SWITZERLAND GMBH·Filed 2020·Granted Oct 12, 2021·14 cites·19 claims
- 0397US11591340B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2022·Granted Feb 28, 2023·6 cites·27 claims
- 0496US11673951B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2019·Granted Jun 13, 2023·8 cites·11 claims
- 0596US10927117B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2017·Granted Feb 23, 2021·18 cites·6 claims
- 0695US11814389B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2022·Granted Nov 14, 2023·3 cites·8 claims
- 0791US2025059277A1Anti-pd1 antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 0889US11896596B2Methods of treating B-cell proliferative disorderBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Feb 13, 2024·5 cites·28 claims
- 0989US2024409546A1CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOFBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 1088US12103931B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Oct 1, 2024·0 cites·16 claims
- 1188US11970500B1Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Apr 30, 2024·0 cites·28 claims
- 1288US2025340560A1SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORSBEIGENE SWITZERLAND GMBH·Filed 2025·Application pending·0 cites
- 1388US2024254128A1SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORSBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 1487US11999743B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Jun 4, 2024·0 cites·27 claims
- 1587US2023303689A1Anti-pd1 antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 1685US2023242542A1COMPOSITIONS COMPRISING (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDEBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 1784US11851437B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2022·Granted Dec 26, 2023·0 cites·29 claims
- 1884US11701357B2Treatment of B cell cancers using a combination comprising Btk inhibitorsBEIGENE SWITZERLAND GMBH·Filed 2017·Granted Jul 18, 2023·4 cites·19 claims
- 1983US11884674B2Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE SWITZERLAND GMBH·Filed 2022·Granted Jan 30, 2024·0 cites·28 claims
- 2082US11786529B2Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitorsBEIGENE SWITZERLAND GMBH·Filed 2018·Granted Oct 17, 2023·4 cites·16 claims
- 2180US2022119524A1Anti-pd1 antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2021·Application pending·0 cites
- 2279US2024076375A1Anti-TIM-3 Antibodies and Use ThereofBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 2379US2023013862A1SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORSBEIGENE SWITZERLAND GMBH·Filed 2021·Application pending·0 cites
- 2477US11911386B2Methods of treating B-cell proliferative disorderBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Feb 27, 2024·0 cites·30 claims
- 2576US11786531B1Methods of treating B-cell proliferative disorderBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Oct 17, 2023·0 cites·30 claims
- 2676US2021130363A1CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOFBEIGENE SWITZERLAND GMBH·Filed 2021·Application pending·0 cites
- 2775US12234286B2Anti-TIGIT antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2021·Granted Feb 25, 2025·0 cites·20 claims
- 2875US2024131030A1Methods of treating b-cell proliferative disorderBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 2973US2023149411A1Oral capsule and preparation method thereforBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 3071US12233069B2Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method thereforBEIGENE SWITZERLAND GMBH·Filed 2023·Granted Feb 25, 2025·0 cites·23 claims
- 3169US2023364096A1Use of a combination comprising a btk inhibitor for treating cancersBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 3269US2022251195A1Anti-tigit antibodies and their use as therapeutics and diagnosticsBEIGENE SWITZERLAND GMBH·Filed 2022·Application pending·0 cites
- 3368US2024366769A1Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 3468US2025059199A1Solid forms of a tyk2 inhibitor, method of preparation, and use thereofBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 3568US2025057821A1Methods of treating myeloid malignancies using bcl-2 inhibitorBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 3667US2024301051A1Anti-cldn6 antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 3766US2025075002A1MUC1 and CD16A Antibodies and Methods of UseBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 3866US2024131167A1EGFR Degraders and Associated Methods of UseBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 3966US2024301061A1Anti-cldn6 and anti-cd3 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4066US2024301062A1Anti-cd3 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4165US2025122152A1KAT6 InhibitorsBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4265US2024009197A1Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitorsBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 4364US2025084168A1Stable high concentration sodium chloride formulations containing pd-1 antibody and methods of use thereofBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4464US2025034257A1Stable high concentration arginine formulations containing pd-1 antibody and methods of use thereofBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4563US2024209106A1Anti-cd137 antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 4663US2024190989A1Anti-cea and anti-cd137 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 4763US2024366770A1Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of useBEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 4863US2024190990A1Anti-cea antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 4962US2024368177A15-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5BEIGENE SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 5062US2024209113A1Anti-gpc3 and anti-cd137 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
Showing the top 50 of 84 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →